Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 238

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The Health Burden of Campylobacter Infection and the Impact of Antimicrobial Resistance: Playing Chicken

Ruiz-Palacios, G. M. · 2007 · Clinical Infectious Diseases

Abstract

Campylobacter species are among the most common pathogens in humans and are commensal in birds, swine, and cattle. It is the most common cause of culture-proven bacterial gastroenteritis in developed and developing countries, responsible for 400 million–500 million cases of diarrhea each year. In the United States, >1% of the population acquires the infection each year. Although diarrhea is the most frequent clinical manifestation of Campylobacter species infection, a broad clinical spectrum is associated with this infection, from asymptomatic carriage to systemic illness and bacteremia to localized infection and association with Guillain-Barré syndrome, a severe immunoreactive complication. In the United States, an estimated 2 million cases of campylobacteriosis occur each year. It is the most common bacterial cause of foodborne illness [1]. The overall incidence of laboratory-confirmed Campylobacter infection in 2005 in the United States was 12.7 cases per 100,000 population, representing a 30% decrease since 1996 [2]. However, the incidence of symptomatic Campylobacter species infection has been estimated at 760–1100 cases per 100,000 population [3]. Age-specific rates of Campylobacter jejuni isolation in patients with diarrhea differ among countries. In industrialized countries, C. jejuni is isolated from 5%–16% of children with diarrhea, with a prevalence of infection in healthy children of 0%–1.5% [1]. In children <5 years of age, the incidence of laboratory-confirmed Campylobacter species infection is 43.4 cases per 100,000 person-years (up to 54.3 cases per 100,000 person-years in children <1 year of age), and the associated male-female ratio is 1.34 : 1 [4]. It is the third most common cause of hospitalization for gastroenteritis after rotavirus and Salmonella species infection, with a hospitalization rate of 10.8% for all Campylobacter species infections [5–7]. Studies of the disease burden of Campylobacter species infection in The Netherlands have estimated that intestinal infection in general accounts for 67,000 disability-adjusted life years per year and that Campylobacter species infections represent at least one-third of the disease burden of all intestinal infections [8]. The cost per case of gastrointestinal infection in Europe has been estimated to be US$94–US$132. In England, the total cost of gastrointestinal infections was estimated to be US$1.23 billion each year. Of this amount, US$116 million is spent on cases of Campylobacter species infection, the highest cost associated with a particular pathogen (including rotavirus and Salmonella) [9]. Campylobacter species infection is generally associated with mild illness and only occasionally is fatal [10]. The mortality rate associated with symptomatic Campylobacter species infection has been estimated at 24 deaths per 10,000 culture-confirmed cases, or 200 deaths per year in the United States [3]. In areas of endemicity in developing countries, the isolation rate in children with diarrhea is 8%–45%, with a similar rate of isolation in asymptomatic children [11–14]. Infections occur early in life, with the highest proportion of C. jejuni isolates obtained from children <5 years of age [12–14]. The annual incidence of Campylobacter species infections can be as high as 2.1 episodes per child. Infections acquired early in life are more likely to be associated with diarrhea, whereas those occurring beyond the age of 4 years, although relatively common, are mostly asymptomatic [12]. Rehydration and correction of electrolyte abnormalities are the mainstay of treatment of patients with Campylobacter species enteritis. Debate exists over the need to administer antimicrobial agents in uncomplicated infections. Antibiotic treatment should be considered for C. jejuni–infected patients who have bloody diarrhea, fever, worsening of symptoms, or a large number of stools, or in those who are immunosuppressed. Campylobacter species are often resistant to penicillin, ampicillin, and cephalosporins, as a result of an alarming increase in fluoroquinolone resistance in the past decade in most countries [15]. This increase in fluoroquinolone resistance coincides with the recent licensure of fluoroquinolones (sarafloxacin and enrofloxacin) for use in poultry and in veterinary medicine in general, which has increased the reservoir of resistant Campylobacter species [16]. Most strains of C. jejuni and Campylobacter coli are susceptible to erythromycin, azithromycin, gentamicin, tetracycline, and chloramphenicol [17]. When antibiotic therapy is indicated, erythromycin is the drug of choice and is administered for 5–7 days [18]. Campylobacter species have little propensity to select for plasmid-mediated resistance to erythromycin, although resistance to this antibiotic has been reported in many countries where it is used indiscriminately [19]. Studies have shown no clinical benefit of erythromycin therapy versus placebo if administered late in the course of illness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/509936

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 238

Metadata

Authors
Ruiz-Palacios, G. M.
Venue
Clinical Infectious Diseases
Published
2007-03-01
Volume
44
Issue
5
Pages
701-703
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2142250977
Cited by
238
References
2
FWCI
9.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.